Sutro Biopharma, Inc. (STRO) 

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Show less

Over the last 12 months, insiders at Sutro Biopharma, Inc. have bought $0 and sold $186,802 worth of Sutro Biopharma, Inc. stock.

On average, over the past 5 years, insiders at Sutro Biopharma, Inc. have bought $365,002 and sold $7.34M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 20,000 shares for transaction amount of $155,016 was made by NEWELL WILLIAM J (CEO) on 2022‑03‑14.